Medical Marijuana Statistics 2020, Usage, Trends and Data

In 2018, the sales of cannabis amounted to nearly 10 billion U.S. dollars and is expected to reach 14.5 in 2020.

(New Frontier Data, 2018)

As of 2017, it was found that real estate and renovations hold the biggest share of startup cost for medical and recreational marijuana retailers in the U.S. for those growing it in-house or without producing infused products, representing 40% of the total startup cost.

(Marijuana Business Daily, 2017)

• In 2018, it was estimated that the marijana retail sales generated up to 4.5 billion U.S. dollars, and is expected to reach 5.5 in the following year. (Marijuana Business Daily, 2018)
• By 2022, the marijuana retail sales is expected to grow substantially, amounting to 7.3 billion U.S. dollars, up from the estimated 6.1 billion U.S. dollars in 2020. (Marijuana Business Daily, 2018)

• It was expected that the market size of cannabinoid-based pharmaceuticals in 2020 could generate up to 2 billion U.S. dollars. (Ackrell Capital, 2016)
• In 2025, the market size of cannabinoid-based pharmaceuticals was estimated to generate a market of 25 billion U.S. dollars, and is expected to double that amount (50 billion U.S. dollars) by 2029. (Ackrell Capital, 2016)

• As of 2017, testing labs had the lowest number of medical cannabis business in the U.S. with a range of only between 100 and 150 business in that business category. (Marijuana Business Daily, 2017)
• Ancillary services, technology and products had the highest number of medical cannabis business in the U.S. as of 2017, with a recorded number of businesses between 13,000 to 18,000. (Marijuana Business Daily, 2017)
• Medical dispensaries/recreational stores had the second-highest number of medical cannabis businesses in the U.S., with a range between 3,300 and 4,300 businesses in total in that category as of 2017. (Marijuana Business Daily, 2017)
• Overall, there were between 20,000 and 28,000 medical cannabis businesses in the U.S. as of 2017. (Marijuana Business Daily, 2017)

• It was found that Canop Growth and Tilray, both Canadian companies, were the top two marijuana companies based on market share as of end-2018. (24/7 Wall St.; Various sources, 2018)
• Canopy Growth was recorded to have a total market capitalization of 9.3 billion U.S. dollars at year-end 2018, ranking first among the top 10 U.S. and Canadian Marijuana Companies with the Highest Market Capitalization. (24/7 Wall St.; Various sources, 2018)
• Tilray ranked second among the top 10 U.S. and Canadian marijuana companies with the highest market capitalization at year-end 2018, with a recorded 6.6 billion U.S. dollars of market capitalization. (24/7 Wall St.; Various sources, 2018)
• Among all U.S. marijuana companies, Scotts Miracle-Gro had the highest market capitalization at year-end 2018, ranking fourth in the top 10 U.S. and Canadian marijuana companies with the highest market capitazliation at year-end 2018. (24/7 Wall St.; Various sources, 2018)
• Green Organic Dutchman, a Canadian marijuana company, made it to the top 10 list of U.S. and Canadian marijuana companies with the highest market capitalization at year-end 2018. (24/7 Wall St.; Various sources, 2018)

• As of November 2018, the District of Columbia had the highest price per ounce of high-quality marijuana in the U.S., with an average price of $600.7 per ounce. (Price of Weed, 2018)
• Illinois had the second-highest price per ounce of high-quality marijuana in the U.S. as of November 2018, with an average price of $354 per ounce, followed by Connecticut, with an average price of $333.6 per ounce. (Price of Weed, 2018)
• Oregon had the lowest price per ounce of high-quality marijuana in the U.S., with an average price per ounce of only $210.6. (Price of Weed, 2018)

• As of 2018, it was found that Seattle has a legal status with a price of $7.58 per gram of medical/recreational marijuana. (weedindex.io, 2018)
• Denver, with a legal status, ranked second among the list of select large cities in the U.S. as of 2018 with the lowest price of medical/recreational marijuana, with a price of only $7.8 per gram. (weedindex.io, 2018)
• Washington DC only had a partial status as of 2018 but it has the highest price per gram of marijuana, reaching up to $18.08 per gram of medical/recreational marijuana. (weedindex.io, 2018)
• Chicago and Philadelpia both had a partial status as of 2018 and ranked second and third among the marijuana prices in select large cities in the U.S., with prices at $11.5 and $11.3 per gram, respectively. (weedindex.io, 2018)

• Between 1995 and 2015, it was found that there was a huge decrease in teenage marijuana use in 13 U.S. states after medical marijuana laws were passed (Marijuana Policy Project, 2015)
• Teenage marijuana use in Alaska went down from 29% in 1998 to only 20% in 2015 after medical marijuana laws were passed. (Marijuana Policy Project, 2015)
• Colorado, Connecticut, New Jersey, and New Mexico were found to have noticeable higher teenage marijuana use after medical marijuana laws were passed. (Marijuana Policy Project, 2015)
• New Mexico had the highest rate of increase in usage of marijuana in the U.S. even after medical marijuana laws were passed, from 26% in 2007 to 28% as of 2015. (Marijuana Policy Project, 2015)

• Between 2010 and 2013, physicians in state with medical marijuana laws prescribed 1,826 fewer doses of drugs annually to treat pain than in states without medical marijuana law. (Health Affairs; Washington Post, 2013)
• Between 2010 and 2013, physicians in state with medical marijuana laws prescribed the least doses of drugs annually to treat spasticity, only 32 doses fewer than in states without medical marijuana law. (Health Affairs; Washington Post, 2013)
• Between 2010 and 2013, physicians in state with medical marijuana laws prescribed 562 fewer doses of drugs annually to treat anxiety than in states without medical marijuana law. (Health Affairs; Washington Post, 2013)
• Between 2010 and 2013, physicians in state with medical marijuana laws prescribed 541 fewer doses of drugs annually to treat nausea than in states without medical marijuana law. (Health Affairs; Washington Post, 2013)
• Between 2010 and 2013, physicians in state with medical marijuana laws prescribed 486 fewer doses of drugs annually to treat seizures than in states without medical marijuana law. (Health Affairs; Washington Post, 2013)
• Between 2010 and 2013, physicians in state with medical marijuana laws prescribed 265 fewer doses of drugs annually to treat depression than in states without medical marijuana law. (Health Affairs; Washington Post, 2013)

• The price of medical cannabis in New York as of 2018 cost 5,600 U.S. dollars per pound, the most expensive among select state in the U.S. (GMP Securities; New Leaf Data Services; Various sources, 2018)
• The price of medical cannabis in Arizona as of 2018 only cost 1,696 U.S. dollars per pound, the cheapest among the select state in the U.S. (GMP Securities; New Leaf Data Services; Various sources, 2018)
• As of 2018, the price of medical cannabis in Florida was recorded to be at 2,813 U.S. dollars per pound while the price in New Mexico sits at 2,857 U.S. dollars per pound. (GMP Securities; New Leaf Data Services; Various sources, 2018)
• The price per pound of U.S. medical cannabis in New Hampshire and Illinois as of 2018 cost 3,105 U.S. dollars and 3,058 U.S. dollars per pound, respectively. (GMP Securities; New Leaf Data Services; Various sources, 2018)
• The price of medical cannabis in Michigan as of 2018 was at 1,824 U.S. dollars per pound. (GMP Securities; New Leaf Data Services; Various sources, 2018)

• As of 2018, Florida had the most number of licensed medical cannabis retail in the U.S., with a total of 630 retail licenses, followed by Michigan with a total of 215 retail licenses. (GMP Securities; New Leaf Data Services; Various sources, 2018)
• New Hampshire had the least number of U.S. medical cannabis retail licenses as of 2018, with a record of only 6 retail licenses, followed by Minnesota with 8 recorded retail licenses. (GMP Securities; New Leaf Data Services; Various sources, 2018)
• Michigan had a total of 215 medical cannabis retail linceses as of 2018, the second-highest number of medical cannabis retail licenses in the U.S., followed by Pennsylvania with a record of 198 retail licenses in the same year. (GMP Securities; New Leaf Data Services; Various sources, 2018)
• Arizona had a total of 130 medical cannabis retail icenses as of 2018 while New mexico only had a total count of 71 retail licenses in the same year. (GMP Securities; New Leaf Data Services; Various sources, 2018)

• As of 2018, it was found that the penetration rate of medical cannabis in Michigan was at 2.8%, followed by Arizona, New Mexico, and Montana, all with a penetration rate of 2.4%. (GMP Securities; New Leaf Data Services; Various sources, 2018)
• As of 2018, Minnesota and Pennsylvania had the lowest penetration rate of medical cannabis among select U.S. states, both with a rate of 0.2%. (GMP Securities; New Leaf Data Services; Various sources, 2018)
• It was found that New Jersey, Illinois, and New York had a medical cannabis penetration rate of 0.3% as of 2018. (GMP Securities; New Leaf Data Services; Various sources, 2018)
• As of 2018, Florida and New Hampshire had a medical cannabis penetration rate of 0.6% and 0.4%, respectively, among select U.S. states. (GMP Securities; New Leaf Data Services; Various sources, 2018)

• It was found from 2017 to 2018 that 24% of college students in the U.S. that were receiving mental health services had used marijuana within the past two weeks. (Penn State (Center for Collegiate Mental Health (CCMH)), 2018)

• Michigan had the highest number of medical cannabis production licenses in the U.S. as of 2018, with 215 production licenses issued at the time. (GMP Securities; New Leaf Data Services; Various sources, 2018)
• As of 2018, Montana had the second-highest number of medical cannabis production licenses in the U.S., with 135 production licenses issued at the time. (GMP Securities; New Leaf Data Services; Various sources, 2018)
• As of 2018, Arizona had issued 130 medical cannabis production licenses in the U.S., followed by Maryland with only 37 licenses issued. (GMP Securities; New Leaf Data Services; Various sources, 2018)
• As of 2018, Minnesota had the least number of medical cannabis production licenses issued at the time, with only 2 licenses issued. (GMP Securities; New Leaf Data Services; Various sources, 2018)

• The medical marijuana market size in 2019 was recorded to have reached 9 billion U.S. dollars and is expected to jump to 23 billion U.S. dollars by 2020. (Ackrell Capital, 2016)
• By 2024, the cannabis consumer market in the U.S. is expected to reach 37 billion U.S. dollars, up from 30 billion U.S. dollars in 2022. (Ackrell Capital, 2016)

• As of 2017, Florida’s annual medical marijuana market is expected to be somewhere between 600 million U.S. dollars and 800 million U.S. dollars. (Marijuana Business Daily, 2017)
• Ohio’s annual medical marijuana market was expected to have reached somewhere between 200 million U.S. dollars and 400 million U.S. dollars as of 2017. (Marijuana Business Daily, 2017)
• North Dakota’s annual medical marijuana market was expected to have reached between 10 million U.S. dollars and 20 million U.S. dollars as of 2017. (Marijuana Business Daily, 2017)
• Pennsylvania’s annual medical marijuana market was expected to have reached between 100 million U.S. dollars and 150 million U.S. dollars as of 2017. (Marijuana Business Daily, 2017)

• As of 2018, Rhode Island had 1.6 medical cannabis production licenses per every retail license. (GMP Securities; New Leaf Data Services; Various sources, 2018)
• Hawaii, Arizona, New Hampshire, Michigan, and Montana, all had 1 medical cannabis production licenses per every retail license as of 2018. (GMP Securities; New Leaf Data Services; Various sources, 2018)
• Florida had the least number of medical cannabis production licenses per retail as of 2018, with only 0.03 per every retail license. (GMP Securities; New Leaf Data Services; Various sources, 2018)

• As of 2016, Pandora’s Box had the highest amount of THC in select medical marijuana strains available in the U.S. state of Oregon with 29.7%, followed by Blue Mango with 25.9%. (Ackrell Capital, 2016)
• As of 2016, Blueberry Kush and Albert Walker OG had the highest amount of CBD in select medical marijuana strains available in the U.S. state of Oregon, followed by Jack Herer, with 0.1%. (Ackrell Capital, 2016)

• As of 2017, it was found that real estate and renovations hold the biggest share of startup cost for medical and recreational marijuana retailers in the U.S. for those growing it in-house or without producing infused products, representing 40% of the total startup cost. (Marijuana Business Daily, 2017)
• As of 2017, it was found that inventory hold the second-biggest share of startup cost for medical and recreational marijuana retailers in the U.S. for those growing it in-house or without producing infused products, representing 25% of the total startup cost. (Marijuana Business Daily, 2017).
• Real estate and renovations still hold the biggest share of startup cost for medical and recreational marijuana retailers in the U.S. for standalone retailers, representing 27% of the total startup cost as of 2017. (Marijuana Business Daily, 2017)
• It was also found that inventory hold the second-biggest share of startup cost for medical and recreational marijuana retailers in the U.S. for standalone retailers, representing 20% of the total startup cost. (Marijuana Business Daily, 2017)
• As of 2017, standalone retailers of medical and recreational marijuana retailers in the U.S. value security and surveillance more than those who grow in-house with or without producing infused products, representing 12% and 9%, respectively, of the total breakup or startup cost. (Marijuana Business Daily, 2017)

29% of the cannabis users stated that their favorite aspect of CBD products was that it provided them the best medical relief.

(HelloMD; Brightfield Group, 2017)

The overall sales of branded CBD products amounted to about 172 million U.S. dollars while flower CBD products only generated 68 million U.S. dollars.

(Hemp Business Journal; New Frontier Data, 2018)

• According to 9% Cannabidiol Users in 2017, Care By Design was the top marijuana-derived CBD brand, followed by Bloom Farms according to 7.8% of the respondents. (HelloMD; Brightfield Group, 2017)
• As of 2017, Cheeba Chews was one of the least-popular marijuana-derived CBD brands according to 4.3% of CBD users in the U.S. and abroad (HelloMD; Brightfield Group, 2017)
• Bhang and Mary’s Medicinals were the 2 least marijuana-derived CBD brand in 2017 according to 4.1% and 4% of CBD users, respectively. (HelloMD; Brightfield Group, 2017)

• According to Cannabis Users as of 2017, 16% of them said that they were disinterested in marijuana-derived CBD-only products because it did not get them high. (HelloMD; Brightfield Group, 2017)
• According to Cannabis Users as of 2017, 12% of them said that they were disinterested in marijuana-derived CBD-only products because it’s too expensive. (HelloMD; Brightfield Group, 2017)
• According to Cannabis Users as of 2017, 12% of them said that they were disinterested in marijuana-derived CBD-only products because it doesn’t relax them. (HelloMD; Brightfield Group, 2017)
• According to Cannabis Users as of 2017, 12% of them said that they were disinterested in marijuana-derived CBD-only products because they can’t get it from their local vendor. (HelloMD; Brightfield Group, 2017)

• In 2018, high THC cannabidiol products generated about 77 million U.S. dollars and is expected to generate about 89 million U.S. dollars in 2019 and over 150 million U.S. dollars in 2022. (Hemp Business Journal; New Frontier Data, 2018)
• The variable cannabidiol products in 2022 is expected to generate 210 million U.S. dollars up from the 2019 expected 92 million U.S. dollars. (Hemp Business Journal; New Frontier Data, 2018)
• In 2018, high CBD cannabidiol products generated about 50 million U.S. dollars and is expected to generate about 78 million U.S. dollars in 2019 and over 194 million U.S. dollars in 2022. (Hemp Business Journal; New Frontier Data, 2018)
• Negligible THC products generated about 42 million U.S. dollars in 2018 and is expected to generate 54 million U.S. dollars in 2019 and over 90 million U.S. dollars by 2022. (Hemp Business Journal; New Frontier Data, 2018)

• In 2017, 60% of hemp-based products were sold over the internet or other direct retailers but is expected to go down to 41% by 2022. (Hemp Business Journal; New Frontier Data; SPINS, 2017)
• In 2017, 14% of hemp-laced cannabidiol goods were sold over natural and specialty retail and is forecasted to grow as high as 28% by 2022. (Hemp Business Journal; New Frontier Data; SPINS, 2017)
• It was forecasted that sales of hemp-laced cannabidiol goods in the U.S. will go down to 9% in 2022 from 21% in 2017. (Hemp Business Journal; New Frontier Data; SPINS, 2017)

• In 2017, Tinctures represented the most share of the cannabidiol brands in the U.S, representing 34% of the total sales. (Hemp Business Journal; New Frontier Data, 2017)
• In 2017, candy accounted the second-most highest shares among the cannabidiol brands in the U.S., representing 20% of the total sales, followed by chocolates, representing 15% of the total sales. (Hemp Business Journal; New Frontier Data, 2017)
• Beverages and infused foods only represented 8% of the 2017 total share of sales of cannabidiol brands in the United States. (Hemp Business Journal; New Frontier Data, 2017)

• In 2017, Mary’s Medicinals was the top CBD product brand in the U.S., generating 6.7 million U.S. dollars in sales, followed by Evergreen Herbal, which generated 2.4 million U.S. dollars in the same year. (Hemp Business Journal; New Frontier Data; BDS Analytics, 2017)
• Stratos generated 2.3 million U.S. dollars in sales while Dixie generated 2.1 million U.S. dollars in sales in the U.S, placing 3rd and 4th, respectively, in the list of top CBD product brands in the U.S. in 2017. (Hemp Business Journal; New Frontier Data; BDS Analytics, 2017)

• In 2017, CBD marijuana generated 177 million U.S. dollars of sales and is forecasted to generate 407 million U.S. dollars in 2020, and then over 645 million U.S. dollars in sales by 2022. (Hemp Business Journal; New Frontier Data, 2017)
• In 2017, CBD hemp generated 190 million U.S. dollars of sales and is expected to generate over 450 million U.S. dollars in 2020, and even over 645 million U.S. dollars by 2022. (Hemp Business Journal; New Frontier Data, 2017)
• CBD pharmaceuticals is forecasted to generate 625 million U.S. dollars of sales in 2022, up from the forecasted 340 million U.S. dollars in 2020. (Hemp Business Journal; New Frontier Data, 2017)

• In 2017, 29% of the cannabis users stated that their favorite aspect of CBD products was that it provided them the best medical relief. (HelloMD; Brightfield Group, 2017)
• In 2017, 21.3% of the cannabis users stated that their favorite aspect of CBD products was that it provided them relaxation. (HelloMD; Brightfield Group, 2017)
• In 2017, 19.4% of the cannabis users stated that their favorite aspect of CBD products was that it doesn’t get them high while only 14.1% do not cause anxiety or paranoia. (HelloMD; Brightfield Group, 2017)

• In 2018, the overall sales of branded CBD products amounted to about 172 million U.S. dollars while flower CBD products only generated 68 million U.S. dollars. (Hemp Business Journal; New Frontier Data, 2018)
• In 2019, the overall sales of branded CBD products is expected to reach 234 million U.S. dollars and is expected to generate as much as 515 million U.S. dollars by 2022. (Hemp Business Journal; New Frontier Data, 2018)
• In 2019, the overall sales of flower CBD products is expected to reach 79 million U.S. dollars and is expected to generate 133 million U.S. dollars by 2022. (Hemp Business Journal; New Frontier Data, 2018)

• It was estimated that the 2018 sales of marijuana-derived CBD will reach 240 million U.S. dollars while the hemp-derived CBD will amount to 264 million U.S. dollars. (Hemp Business Journal; New Frontier Data, 2017)
• By 2022, the estimated that the sales of marijuana-derived CBD and hemp-derived CBD will amount to 647 million U.S. dollars and 646 million U.S. dollars, respectively. (Hemp Business Journal; New Frontier Data, 2017)
• The estimated sales of pharmaceuticals in 2018 was estimated to amount to 30 million U.S. dollars and is expected to reach 625 million U.S. dollars by 2022. (Hemp Business Journal; New Frontier Data, 2017)

• The 2017 cannabidiol product sales for adult-use in the U.S. amounted to 54 million U.S. dollars and is estimated to reach 295 million U.S. dollars by 2022. (Hemp Business Journal; New Frontier Data, 2017)
• The 2017 cannabidiol product sales for medical use in the U.S. amounted to 124 million U.S. dollars and is estimated to reach 352 million U.S. dollars by 2022. (Hemp Business Journal; New Frontier Data, 2017)
• It was estimated that the cannabidiol product sales for adult-use and medical use in the U.S. will amount to 150 million U.S. dollars and 257 million U.S. dollars in 2020. (Hemp Business Journal; New Frontier Data, 2017)

• In 2017, it was found that high THC cannabidiol products accounted for 37% of the total sales of cannabidiol products in the US. but is expected to only account for 23% of the total sales by 2022. (Hemp Business Journal; New Frontier Data, 2017)
• In 2022, variable cannabidiol products were estimated to account for 33% of the total sales of cannabidiol in the U.S., up from only 30% in 2017. (Hemp Business Journal; New Frontier Data, 2017)
• High CBD cannabidiol products were expected to account for 30% of the 2022 total sales of cannabidiol products in the U.S., up from 17% in the 2017. (Hemp Business Journal; New Frontier Data, 2017)
• Negligible THC represented 16% of the 2017 total sales of cannabidiol products in the U.S. and is expected to go down to 14% by 2022. (Hemp Business Journal; New Frontier Data, 2017)

As of July 2019, it was found that 3.71% of the population in Oklahoma were medical marijuana patients.

(Marijuana Policy Project, 2018)

In 2017, it was found that 63% of U.S. Iraq and Afghanistan veterans support the legalization of medical marijuana compared to only 15% of the same respondent that don’t.

(IAVA; George Mason University, 2017)

• As of May 2018, California had the highest number of legal medical marijuana patients, with 915,845 patients recorded, followed by Michigan, with 269,553 confirmed counts. (ProCon; Various sources, 2018)
• Alaska had the least number of legal medical marijuana patients in the U.S., with only 1,054 counted patients as of May 2018. (ProCon; Various sources, 2018)
• Florida ranked 3rd among the list of states with the highest number of legal medical marijuana patients as of May 2018, with a record of 108.981 patients. (ProCon; Various sources, 2018)

• As of 2017, 86% adults in the U.S. agree that cannabis has valid medical uses while 28% of adults in the U.S. think that cannabis is a dangerous drug. (Marijuana.com; New Frontier Data, 2017)
• As of 2017, 34% of adults in the U.S. think that cannabis is highly addictive while 28% of adults in the U.S. think that if cannabis is legalized, the government should keep track of cannabis users. (Marijuana.com; New Frontier Data, 2017)
• As of 2017, 13% of adults in the U.S. think that people who use cannabis should be arrested while 28% of the same respondent are likely to consider using cannabis if it is legal. (Marijuana.com; New Frontier Data, 2017)

• As of 2017, 74% of U.S. cannabis and opioid patients strongly agree that using cannabis in conjunction with or as a substitute for opiate use while only 23% agrees. (Expert(s); Cannabis and Cannabinoid Research, 2017)
• As of 2017, 72% of U.S. cannabis and opioid patients strongly agree that they would use cannabis more in conjunction with or as a substitute for opiate use if available compared to 21% that agrees. (Expert(s); Cannabis and Cannabinoid Research, 2017)
• As of 2017, 70% of U.S. cannabis and opioid patients strongly agree that cannabis side effects are more tolerable than opiates and that they would use cannabis more in conjunction with or as a substitute for opiate use while 22% said they would only agree. (Expert(s); Cannabis and Cannabinoid Research, 2017)

• As of 2017, 68% of U.S. cannabis and nonopioid using patients strongly agree that they will use cannabis as a substitute for or in conjunction with nonopioid pain medication if it’s available compared to 25% who only agrees. (Expert(s); Cannabis and Cannabinoid Research, 2017)
• As of 2017, 67% of U.S. cannabis and nonopioid using patients strongly agree that they will use and even prefer cannabis to nonopiod paid medication while only 28% agrees. (Expert(s); Cannabis and Cannabinoid Research, 2017)
• As of 2017, only 42% of U.S. cannabis and nonopioid using patients strongly agree that cannabis works well with their nonopiod paid medication while 48% said they agree. (Expert(s); Cannabis and Cannabinoid Research, 2017)

• As of 2017, 38% of older adults in the U.S. think that medical marijuana probably provides pain relief compared to 27% that are unsure about its effects. (GfK; IHPI, 2017)
• As of 2017, 31% of older adults in the U.S. think that medical marijuana definitely provides pain relief compared to only 4% that says it doesn’t provide any pain relief effects. (GfK; IHPI, 2017)

• It was found from 1995 to 2015 that those in favor of medical marijuana in the U.S. never dropped below 70%. (Marijuana Policy Project, 2015)
• A poll from Fox News in May 2013 revealed that 85% of respondents in the U.S. show they were in favor of the approval of medical marijuana in the U.S. (Marijuana Policy Project, 2015)
• The latest poll by CBS News in April 2015 revealed that 84% of respondents in the U.S. were in favor of the approval of medical marijuana. (Marijuana Policy Project, 2015)

• As of May 2018, it was found that Maine had the highest rate of legal medication marijuana, with 38 patients per 1,000 state residents. (ProCon; Various sources, 2018)
• As of May 2018, it was found that Michigan had the second-highest rate of legal medication marijuana, with 27 patients per 1,000 state residents. (ProCon; Various sources, 2018)
• As of May 2018, it was found that Alaska, Arkansas, Illinois, and Minnesoata had the lowest rate of legal medication marijuana, with only 1 patient per 1,000 state residents. (ProCon; Various sources, 2018)

• As of 2018, 49% among cancer patients thought that their symptoms were managed somewhat well by medical marijuana, compared to 6% that said not very well. (American Society of Clinical Oncology; Harris Poll, 2018)
• As of 2018, 44% among cancer patients thought that their symptoms were managed very well by medical marijuana, compared to 6% that said not at all very well. (American Society of Clinical Oncology; Harris Poll, 2018)

• A 2018 data revealed that 60% among those prescription opioid users don’t have any trouble accessing their opioid medication while 40% were having trouble accessing it. (American Society of Clinical Oncology; Harris Poll, 2018)
• A 2018 data revealed that 52% among those prescription medical marijuana users don’t have any trouble accessing their medical marijuana medication while 48% were having trouble accessing their medication. (American Society of Clinical Oncology; Harris Poll, 2018)

• As of 2018, in total, 83% of adults support the use of medical marijuana among cancer patients alone while 76% support the use of medical marijuana for any medical reason. (American Society of Clinical Oncology; Harris Poll, 2018)
• As of 2018, 81% of adults between ages 18 and 37 years old support the use of medical marijuana among cancer patients alone compared to 75% that support the use of medical marijuana for any medical reason. (American Society of Clinical Oncology; Harris Poll, 2018)
• As of 2018, 81% of adults between ages 38 and 53 years old support the use of medical marijuana among cancer patients alone compared to 76% that support the use of medical marijuana for any medical reason. (American Society of Clinical Oncology; Harris Poll, 2018)
• As of 2018, 80% of adults between ages 72 and older support the use of medical marijuana among cancer patients alone compared to 65% that support the use of medical marijuana for any medical reason. (American Society of Clinical Oncology; Harris Poll, 2018)

• It was found from a 2018 survey that 87% of caregivers and 87% of those who have/had cancer support the use of medical marijuana for cancer patients. (American Society of Clinical Oncology; Harris Poll, 2018)
• As of 2018, 86% of respondents say that they support the use of medical marijuana to treat a family member/loved one who had cancer while 82% of respondents with no cancer experience also say that they support the use of medical marijuana among cancer patients. (American Society of Clinical Oncology; Harris Poll, 2018)
• As of 2018, 83% of caregivers say that they support the use of medical marijuana for any medical reason while only 74% say the same among patients who have/had cancer. (American Society of Clinical Oncology; Harris Poll, 2018)
• As of 2018, 62% of patients who have/had cancer say they were open to using medical marijuana to alleviate their cancer-related pain, nausea or other symptoms compared to 58% that say they wish they had more information about the benefits of using medical marijuana to alleviate said health issues. (American Society of Clinical Oncology; Harris Poll, 2018)

• According to the 2018 data, it was found that Michigan had the highest number of medical cannabis patients in the U.S., with over 277,000 confirmed cases. (GMP Securities; New Leaf Data Services; Various sources, 2018)
• Arizona had the second-highest number of confirmed medical cannabis patients in the U.S., with 169,478 confirmed cases as of 2018. (GMP Securities; New Leaf Data Services; Various sources, 2018)
• New York had 62,256 confirmed cases of medical cannabis patients as of 2018, followed by New Mexico, with 50,954 confirmed cases of the same year. (GMP Securities; New Leaf Data Services; Various sources, 2018)
• As of 2018, New Hampshire had the least number of confirmed medical cannabis patients in the U.S., with only 4,753 confirmed accounts. (GMP Securities; New Leaf Data Services; Various sources, 2018)

• It was found that 48% of older U.S. adults felt prescription pain medication was more effective at treating pain then marijuana as of 2017 compared to 14% that felt marijuana is more effective. (GfK; IHPI, 2017)
• As of 2017, it was found that 38% of older adults in the U.S. felt both marijuana and prescription pain medication have the same effects. (GfK; IHPI, 2017)

• It was found that 57% of older adults in the U.S. felt prescription pain medication had more side effects than marijuana in treating pain as of 2017 compared to only 14% that say marijuana has more side-effects. (GfK; IHPI, 2017)
• As of 2017, 34% of older adults in the U.S. felt that both marijuana and prescription pain medication have about the same side-effects. (GfK; IHPI, 2017)

• Only 13% of older adults in the U.S. felt that marijuana is more addictive than prescription medicine compared to 48% that say prescription pain medication is more addictive as of 2017. (GfK; IHPI, 2017)
• 38% of older adults in the U.S. as of 2017 say that both marijuana medication and prescription pain medication are equally addictive. (GfK; IHPI, 2017)

• 25% of Minnesota-based healthcare practitioners perceive medical cannabis as a great deal of benefits for their clients compared to only 9% that don’t see benefit in it as of 2017. (MDH, 2017)

• As of 2017, 56% of Minnesota-based medical cannabis patients cited pain reduction as the primary benefit of medical cannabis compared to 1% saying nausea/vomiting/improved appetite is the primary benefit of medical cannabis. (MDH, 2017)
• As of 2017, 10% of Minnesota-based medical cannabis patients cited improvement of sleep as the primary benefit of medical cannabis while only 4% cited reduction of anxiety. (MDH, 2017)

• As of 2017, 37% of respondents indicated that they felt there was a “great deal of benefit” in using medical cannabis to treat their pain compared to 5% that say it has the “least deal of benefit” in using medical cannabis to treat pain. (MDH, 2017)

• It was found as of 2017 that 22% of patients said that negative physical side effects of cannabis were an important issues compared to 13% that said mental side effects of cannabis were a more important issue. (MDH, 2017)
• As of 2017, only 9% of patients said that access-related issues were an important issue. (MDH, 2017)

• As of 2017, 17% of physicians surveyed said that negative physical side effects of cannabis were an important issue compared to 10% that say mental side effects were a more important issue. (MDH, 2017)

• As of 2017, 44% of older adults in the U.S. stated that they would consider asking their health care provider about marijuana if they had a serious health confition compared to only 13% that wouldn’t consider. (GfK; IHPI, 2017)

• As of December 2016, it was found that there were 342,976 confirmed newly applied medical marijuana patients in Colorado, up from December 2015’s recorded 317,300 newly applied medical marijuana. (CDPHE, 2016)
• It was found in December 2016 that the number of newly applied medical marijuana patients in Colorado since May 2015 had increased by 15%, totaling 342,976 in December 2016. (CDPHE, 2016)

• As of January 2017, 62% of respondents in the U.S. between ages 18-34 years old are likely to recommend cannabis to a friend compared to 51% of respondents in the U.S. ages 35 years old and up. (New Frontier Data, 2017)

• As of July 2019, it was found that 3.71% of the population in Oklahoma were medical marijuana patients. (Marijuana Policy Project, 2018)
• As of July 2019, it was found that 3.44% of the population in California were medical marijuana patients while 3.43% of the population in Maine were medical marijuana patients. (Marijuana Policy Project, 2018)
• As of July 2019, it was found that only 0.08% of the population in Alaska were medical marijuana patients, the least number of patients in the U.S. (Marijuana Policy Project, 2018)

• In 2017, it was found that 63% of U.S. Iraq and Afghanistan veterans support the legalization of medical marijuana compared to only 15% of the same respondent that don’t. (IAVA; George Mason University, 2017)
• In 2017, it was found that 44% of U.S. Iraq and Afghanistan veterans support the legalization of medical marijuana for recreational purposes compared to 30% that oppose the idea. (IAVA; George Mason University, 2017)
• In 2017, it was found that 48% of U.S. Iraq and Afghanistan veterans are neutral about the the legalization of medical marijuana. (IAVA; George Mason University, 2017)

As of July 2019, it was found that 3.71% of the population in Oklahoma were medical marijuana patients.

(Marijuana Policy Project, 2018)

As of 2017, 53% of respondents from regulated dispensaries said that regulated dispensaries are very profitable compared to 6% that said they’re losing a lot of money.

(Marijuana Business Daily, 2017)

• As of May 2017, Colorado was recorded to have the most number of medical marijuana dispensaries open in the U.S., with a record of 515 open dispensaries. (Expert(s); SIU, 2017)
• Ohio was recorded to have the second-highest number of medical marijuana dispensaries open in the U.S., with a total of 400 open dispensaries as of May 2017. (Expert(s); SIU, 2017)
• Oregon was recorded to have the third-highest number of medical marijuana dispensaries open in the U.S., with a total of 345 open dispensaries as of May 2017. (Expert(s); SIU, 2017)
• Delaware was recorded to have the least number of medical marijuana dispensaries open in the U.S., with a total of only 1 open dispensaries as of May 2017. (Expert(s); SIU, 2017)

• As of 2017, the startup cost for businesses launched in the past three years among regulated medical marijuana dispensaries in the U.S. were about 775,000 U.S. dollars compared to unregulated medical marijuana dispensaries that only cost 100,000 U.S. dollars. (Marijuana Business Daily, 2017)
• The annual revenue of regulated medical marijuana dispensaries in the U.S. as of 2017 was recorded to hit over 3 million U.S. dollars, compared to unregulated medical marijuana dispensaries in the U.S. that only generated an annual revenue of 740,000 U.S. dollars. (Marijuana Business Daily, 2017)
• As of 2017, it was found that the annual operating expenses of regulated medical marijuana dispensaries generated over 1.9 million U.S. dollars, compared to unregulated medical marijuana dispensaries that only generated 400,000 U.S. dollars. (Marijuana Business Daily, 2017)

• It was found as of 2017 that regulated medical marijuana dispensaries in the U.S. had an average of 3,150 monthly customers and about 37,800 yearly customers. (Marijuana Business Daily, 2017)
• It was found as of 2017 that unregulated medical marijuana dispensaries in the U.S. had an average of 2,010 monthly customers and about 24,120 yearly customers. (Marijuana Business Daily, 2017)

• A 2017 survey revealed that about 57% of unregulated medical marijuana dispensaries in the U.S. only accepts cash payments, compared to 25% saying they only accept debit and 29% saying they only accept credit. (Marijuana Business Daily, 2017)
• A 2017 survey revealed that about 43% of regulated medical marijuana dispensaries in the U.S. only accepts cash payments, compared to 52% saying they only accept debit and 22% saying they only accept credit. (Marijuana Business Daily, 2017)
• It was found as of 2017 that 14% of unregulated medical marijuana dispensaries in the U.S. only accepts other forms of payment. (Marijuana Business Daily, 2017)

• Among the 33 states that had legalized marijuana in the U.S., Washington, D.C. had the most expensive price of legal marijuana from dispensaries in the U.S. as of June 2018, with an average price per ounce of 506 U.S. dollars. (Various sources (Honest Marijuana Company), 2019)
• Among the 33 states that had legalized marijuana in the U.S., Oregon had the lowest legal cost of legal marijuana from dispensaries in the U.S. as of June 2018, with an average price per ounce of 186 U.S. dollars. (Various sources (Honest Marijuana Company), 2019)
• As of June 2018, it was found that Alaska had an average price of 303 U.S. dollars per ounce of legal marijuana from dispensaries among the 33 states that had legalized marijuana in the U.S. (Various sources (Honest Marijuana Company), 2019)

• As of 2017, Arizona had the highest medical marijuana dispensary annual revenue, which generated over 3.5 million U.S. dollars, followed by Maine at 3.37 million U.S. dollars. (Marijuana Business Daily, 2017)
• Washington, D.C. was recorded to have generated an annual revenue of about 2 million U.S. dollars as of 2017 from medical marijuana dispensaries in the U.S. (Marijuana Business Daily, 2017)
• Michigan and New Mexico both generated an annual revenue of 1.2 million U.S. dollars from medical marijuana dispensary in the U.S. as of 2017. (Marijuana Business Daily, 2017)
• Montana generated the least annual revenue in medical marijuana dispensary in the U.S. with only about 225,000 U.S. dollars as of 2017. (Marijuana Business Daily, 2017)

• As of 2017, 53% of respondents from regulated dispensaries said that regulated dispensaries are very profitable compared to 6% that said they’re losing a lot of money. (Marijuana Business Daily, 2017)
• Only 27% of respondents from unregulated dispensaries said that unregulated medical marijuana dispensaries are very profitable. as of 2017 compared to 8% that said they’re losing a lot of money. (Marijuana Business Daily, 2017)
• It was found that as of 2017, 42% of respondents from unregulated dispensaries said that unregulated medical marijuana dispensaries are only breaking even. (Marijuana Business Daily, 2017)

(CDPHE, 2018)

• As of June 2019, 92% of medical marijuana patients in Colorado reported having severe pains while only 31% reported having muscle spasms. (CDPHE, 2018)
• As of June 2019, 14% of medical marijuana patients in Colorado reported having severe nausea while only 7% reported having PTSD. (CDPHE, 2018)
• As of June 2019, only 1% of medical marijuana patients in Colorado reported having cachexia or glaucoma. (CDPHE, 2018)
• As of June 2019, only 4% of medical marijuana patients in Colorado reported having cancer. (CDPHE, 2018)

• In December 2017, the total marijuana revenue from licenses, fees, and taxes in the state of Colorado amounted to over 21 million U.S. dollars. (Colorado Department of Revenue, 2017)
• It was in August 2017 that the state of Colorado’s revenue from licenses, fees, and taxes amounted the highest from January to December 2017, approximately 23.76 million U.S. dollars. (Colorado Department of Revenue, 2017)
• It was in March 2017 that the state of Colorado’s revenue from licenses, fees, and taxes amounted the lowest from January to December 2017, approximately 17.55 million U.S. dollars. (Colorado Department of Revenue, 2017)

• It was found in 2018 that Colorado represented 15.1% of the total U.S. legal cannabis market, and is expected to go down to 12.7% in 2019. (New Frontier Data, 2016)
• Colorado’s share in the total U.S. legal cannabis market in 2020 is forecasted to go down to 11%, and 8.1% by 2025. (New Frontier Data, 2016)

• The price for high quality marijuana in Denver stood at 500 U.S. dollars per ounce on October 9, 2018 and down to 250 U.S. dollars just 2 days later. (Price of Weed, 2018)
• As of 2018, medium quality marijuana in Pueblo was found to cost around 75 U.S. dollars per ounce while the same quality marijuana in Boulder was recorded to cost 93 U.S. dollars per ounce. (Price of Weed, 2018)
• In November 2018, the average price per ounce of marijuana in Denver, Colorado was recorded to cost around 100 U.S. dollars per ounce. (Price of Weed, 2018)

• In December 2018, there were 86,641 confirmed number of medical marijuana patients in Colorado, down from 93,372 in December 2017, the highest record of currect, active medical marijuana patients in Colorado’s history from January 2017 to December 2018. (CDPHE, 2018)
• In February 2017, there were 78,369 medical marijuana patients in Colorado, the lowest recorded number of medical marijuana patients between January 2017 and December 2018. (CDPHE, 2018)

• The total sales of medical and recreational marijuana in the state of Colorado in 2017 reached over 1.5 billion U.S dollars, up from the previous year’s over 1.3 billion U.S. dollars. (The Cannabist; Colorado Department of Revenue; Denver Post, 2017)
• The total sales of medical marijuana in the state of Colorado in 2017 reached over 416 million U.S. dollars, down from last year’s 438 million U.S. dollars. (The Cannabist; Colorado Department of Revenue; Denver Post, 2017)
• The total sales of recreational marijuana in the state of Colorado in 2017 only a little over 1 million U.S. dollars, down from the previous year’s 875 million U.S. dollars. (The Cannabist; Colorado Department of Revenue; Denver Post, 2017)

• As of April 2019, there were a total of 28,156 patients with mailing addresses in the state of Oregon and only 21 patients with mailing address outside Oregon. (Oregon Health Authority, 2019)
• As of April 2019, there were a total of 11,501 caregivers with mailing addresses in the state of Oregon and only 63 caregivers with mailing address outside Oregon. (Oregon Health Authority, 2019)
• As of April 2019, there were a total of 12,846 growsers with mailing addresses in the state of Oregon and only 13 caregivers with mailing address outside Oregon. (Oregon Health Authority, 2019)
• As of April 2019, there were a total of 10,900 grow sites with mailing addresses inside the state of Oregon. (Oregon Health Authority, 2019)

• Among the medical marijuana patients registered in Oregon as of April 2019, 87% of them were treated for severe pain. (Oregon Health Authority, 2019)
• Among the medical marijuana patients registered in Oregon as of April 2019, 20% of them were treated for spasms. (Oregon Health Authority, 2019)
• Among the medical marijuana patients registered in Oregon as of April 2019, 12% of them were treated for PTSD. (Oregon Health Authority, 2019)

• As of April 2019, medical marijuana patients registered in Oregon aged between 60 and 64 years old made up the largest portion of medical marijuana patients in the state, making up almost 13% of the total, followed by patients aged 65 and 69 years old that made up 12%. (Oregon Health Authority, 2019)
• As of April 2019, medical marijuana patients registered in Oregon aged between 80 years old and over made up the smallest portion of medical marijuana patients in the state, making up only 1% of the total, same for patients aged between 18 and 20 years old, which also covered about 1% of the total. (Oregon Health Authority, 2019)

• In 2017, the state of Oregon covered 9.7% of the total U.S. legal cannabis market but is expected to go down to only 6% by 2020. (New Frontier Data, 2016)
• By 2025, the state of Oregon is forecasted to cover only 4.3% of the total U.S. legal cannabis market, down from the forecasted 4.5% in 2024. (New Frontier Data, 2016)

• As of October 22, 2018, the average price per ounce of medium quality marijuana in Portland, Oregon was 800 dollars per ounce when it was only at 150 U.S. dollars just 3 days ago. (Price of Weed, 2018)
• As of 2018, the average price per ounce of medium quality marijuana in Tualatin and Salem was about 100 U.S. dollars and 75 U.S. dollars per ounce, respectively. (Price of Weed, 2018)
• As of September 30, 2018, the average price per ounce of medium quality marijuana in Portland, Oregon was 80 dollars per ounce. (Price of Weed, 2018)
• As of 2018, the average price per ounce of high quality marijuana in Eugene, Oregon was about 150 dollars per ounce, same as low quality marijuana in Elgin, Oregon. (Price of Weed, 2018)